# Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

> **NCT00651014** · PHASE4 · TERMINATED · sponsor: **Organon and Co** · enrollment: 82 (actual)

## Conditions studied

- Hypercholesterolemia
- Atherosclerosis

## Interventions

- **DRUG:** Ezetimibe
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00651014
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** slow subject recruitment and lack of medical and scientific merit due to change in new standard of therapy during that same period.
- **Last updated:** 2022-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651014, "Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00651014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*